Budget Impact and Cost-Effectiveness of Intravenous Meloxicam to Treat Moderate-Severe Postoperative Pain

Overview

Journal Adv Ther

Date 2022 Jun 9

PMID 35678995

Authors

John A Carter

Libby K Black

Kathleen L Deering

Jonathan S Jahr

Affiliations

Soon will be listed here.

Abstract

Introduction: This study assesses the budget impact and cost-effectiveness of intravenous meloxicam (MIV) to treat moderate-severe acute postoperative pain in adults.

Methods: A two-part Markov cohort model captured the pharmacoeconomic impact of MIV versus non-opioid intravenous analgesics (acetaminophen, ibuprofen, ketorolac) among a hypothetical adult cohort undergoing selected inpatient procedures and experiencing moderate-severe acute postoperative pain: Part 1 (postoperative hour 0 to discharge, cycled hourly), health states were defined by pain level. Pain transition rates, adverse event probabilities, and concomitant opioid utilization were derived from a network meta-analysis. Part 2 (discharge to week 52, cycled weekly), health states were defined by the presence/absence of pain-related readmission and opioid use disorder as determined by literature-based inputs relating to pain control outcomes. Healthcare utilization and direct medical costs were derived from an administrative claims database analysis. Primary outcomes were the incremental cost per member per month (PMPM) and cost per quality-adjusted life year (QALY) gained. Scenario, univariate, and probabilistic sensitivity analyses were conducted. The model assumed a private payer perspective in the USA (no discounting, 2019 US$).

Results: Modeled outcomes indicated MIV was associated with lower accumulated postoperative pain, fewer adverse events, and less opioid utilization for most procedures and comparators, with longer-term outcomes also generally favoring MIV. The budget impact of MIV was - $0.028 PMPM. From a cost-effectiveness perspective, MIV had lower costs and better outcomes for all comparisons except against ketorolac in orthopedic procedures where the former was cost-effective but not cost saving ($95,925/QALY). Scenario and sensitivity analyses indicated that modeled outcomes were robust to alternative inputs and underlying input uncertainty. Differences in direct medical costs were driven by reduced costs attributable to length of stay and opioid-related adverse drug events.

Conclusion: MIV was associated with modeled clinical and economic benefits compared to commonly used non-opioid intravenous analgesics.

References

Gross J, Gordon D . The Strengths and Weaknesses of Current US Policy to Address Pain. Am J Public Health. 2018; 109(1):66-72. PMC: 6301412. DOI: 10.2105/AJPH.2018.304746. View

Shaffer E, Pham A, Woldman R, Spiegelman A, Strassels S, Wan G . Estimating the Effect of Intravenous Acetaminophen for Postoperative Pain Management on Length of Stay and Inpatient Hospital Costs. Adv Ther. 2016; 33(12):2211-2228. PMC: 5126194. DOI: 10.1007/s12325-016-0438-y. View

Kharasch E, Brunt L . Perioperative Opioids and Public Health. Anesthesiology. 2016; 124(4):960-5. DOI: 10.1097/ALN.0000000000001012. View

Apfelbaum J, Chen C, Mehta S, Gan T . Postoperative pain experience: results from a national survey suggest postoperative pain continues to be undermanaged. Anesth Analg. 2003; 97(2):534-540. DOI: 10.1213/01.ANE.0000068822.10113.9E. View

Correll D, Vlassakov K, Kissin I . No evidence of real progress in treatment of acute pain, 1993-2012: scientometric analysis. J Pain Res. 2014; 7:199-210. PMC: 3990387. DOI: 10.2147/JPR.S60842. View

Shafi S, Collinsworth A, Copeland L, Ogola G, Qiu T, Kouznetsova M . Association of Opioid-Related Adverse Drug Events With Clinical and Cost Outcomes Among Surgical Patients in a Large Integrated Health Care Delivery System. JAMA Surg. 2018; 153(8):757-763. PMC: 6142954. DOI: 10.1001/jamasurg.2018.1039. View

Althaus A, Arranz Becker O, Neugebauer E . Distinguishing between pain intensity and pain resolution: using acute post-surgical pain trajectories to predict chronic post-surgical pain. Eur J Pain. 2013; 18(4):513-21. DOI: 10.1002/j.1532-2149.2013.00385.x. View

Hernandez-Boussard T, Graham L, Desai K, Wahl T, Aucoin E, Richman J . The Fifth Vital Sign: Postoperative Pain Predicts 30-day Readmissions and Subsequent Emergency Department Visits. Ann Surg. 2017; 266(3):516-524. PMC: 6530481. DOI: 10.1097/SLA.0000000000002372. View

Morland R . Evolution of the national opioid crisis. Nursing. 2019; 49(5):51-56. DOI: 10.1097/01.NURSE.0000554613.10524.54. View

10.

Roland C, Ye X, Stevens V, Oderda G . The Prevalence and Cost of Medicare Beneficiaries Diagnosed and At Risk for Opioid Abuse, Dependence, and Poisoning. J Manag Care Spec Pharm. 2018; 25(1):18-27. PMC: 10397651. DOI: 10.18553/jmcp.2019.25.1.018. View

11.

Savarese J, Tabler Jr N . Multimodal analgesia as an alternative to the risks of opioid monotherapy in surgical pain management. J Healthc Risk Manag. 2017; 37(1):24-30. DOI: 10.1002/jhrm.21262. View

12.

Hansen R, Pham A, Strassels S, Balaban S, Wan G . Erratum to: Comparative Analysis of Length of Stay and Inpatient Costs for Orthopedic Surgery Patients Treated with IV Acetaminophen and IV Opioids vs. IV Opioids Alone for Post-Operative Pain. Adv Ther. 2016; 33(9):1646-1648. PMC: 5020110. DOI: 10.1007/s12325-016-0400-z. View

13.

Wick E, Grant M, Wu C . Postoperative Multimodal Analgesia Pain Management With Nonopioid Analgesics and Techniques: A Review. JAMA Surg. 2017; 152(7):691-697. DOI: 10.1001/jamasurg.2017.0898. View

14.

Wardhan R, Chelly J . Recent advances in acute pain management: understanding the mechanisms of acute pain, the prescription of opioids, and the role of multimodal pain therapy. F1000Res. 2017; 6:2065. PMC: 5710326. DOI: 10.12688/f1000research.12286.1. View

15.

Wongrakpanich S, Wongrakpanich A, Melhado K, Rangaswami J . A Comprehensive Review of Non-Steroidal Anti-Inflammatory Drug Use in The Elderly. Aging Dis. 2018; 9(1):143-150. PMC: 5772852. DOI: 10.14336/AD.2017.0306. View

16.

Christensen S, Cooper S, Mack R, McCallum S, Du W, Freyer A . A Randomized Double-Blind Controlled Trial of Intravenous Meloxicam in the Treatment of Pain Following Dental Impaction Surgery. J Clin Pharmacol. 2018; 58(5):593-605. PMC: 5947566. DOI: 10.1002/jcph.1058. View

17.

Rechberger T, Mack R, McCallum S, Du W, Freyer A . Analgesic Efficacy and Safety of Intravenous Meloxicam in Subjects With Moderate-to-Severe Pain After Open Abdominal Hysterectomy: A Phase 2 Randomized Clinical Trial. Anesth Analg. 2019; 128(6):1309-1318. PMC: 6530966. DOI: 10.1213/ANE.0000000000003920. View

18.

Gottlieb I, Tunick D, Mack R, McCallum S, Howard C, Freyer A . Evaluation of the safety and efficacy of an intravenous nanocrystal formulation of meloxicam in the management of moderate-to-severe pain after bunionectomy. J Pain Res. 2018; 11:383-393. PMC: 5819580. DOI: 10.2147/JPR.S149879. View

19.

Pollak R, Gottlieb I, Hakakian F, Zimmerman J, McCallum S, Mack R . Efficacy and Safety of Intravenous Meloxicam in Patients With Moderate-to-Severe Pain Following Bunionectomy: A Randomized, Double-Blind, Placebo-controlled Trial. Clin J Pain. 2018; 34(10):918-926. DOI: 10.1097/AJP.0000000000000609. View

20.

Singla N, Bindewald M, Singla S, Leiman D, Minkowitz H, McCallum S . Efficacy and Safety of Intravenous Meloxicam in Subjects with Moderate-to-severe Pain Following Abdominoplasty. Plast Reconstr Surg Glob Open. 2018; 6(6):e1846. PMC: 6157956. DOI: 10.1097/GOX.0000000000001846. View